

Dr. Tolga Sütüü, after graduating from Kadıköy Anadolu Lisesi, received his bachelor's degree in Biological Sciences and Bioengineering from Sabanci University in 2004. Continuing his postgraduate education in Sweden, Dr. Sütüü received his Ph.D. in Medical Science from Karolinska Institutet in 2012 and carried out his postdoctoral work at the Center for Hematology and Regenerative Medicine at Karolinska University Hospital. Upon his return to Turkey, he worked as a research group leader at Sabanci University between 2014-2019. Currently, he is a faculty member in the Department of Molecular Biology and Genetics at Boğaziçi University since September 2019.



His areas of interest focus on immunology in general and cancer immunotherapy in particular. He is closely involved in the design and optimization of biotechnological processes for personalized medicine applications, including the production of monoclonal antibodies for cancer immunotherapy, as well as the targeting of immune system cells to cancer tissue through *ex vivo* propagation and genetic modification.

He has been serving as a board member at the Turkish Society of Immunology since 2016. His notable awards include Science Academy Young Scientists Award Program (BAGEP) in 2017, the METU Parlar Foundation Technology Incentive Award in 2018, the Molecular Cancer Research Association's Basic Cancer Researcher of the Year award, and the JCI International's 10 Outstanding Young Persons of Turkey award in 2019.

Relevant Literature:

1. Nahi H, Chrobok M, Meinke S, Gran C, Marquardt N, Afram G, **Sutlu T**, Gilljam M, Stellan B, Wagner AK, Blomberg P, Holmqvist PH, Walther-Jallow L, Mellström K, Liwing J, Gustafsson C, Mansson R, Klimkowska M, Gahrton G, Lund J, Ljungman P, Ljunggren HG, Alici E. Autologous NK cells as consolidation therapy following stem cell transplantation in multiple myeloma. *Cell Rep Med*. 2022 Jan 28;3(2):100508. doi: 10.1016/j.xcrm.2022.100508.
2. Sayitoglu EC, Georgoudaki AM, Chrobok M, Ozkazanc D, Josey BJ, Arif M, Kusser K, Hartman M, Chinn TM, Potens R, Pamukcu C, Krueger R, Zhang C, Mardinoglu A, Alici E, Temple HT, **Sutlu T**, Duru AD. Boosting Natural Killer Cell-Mediated Targeting of Sarcoma Through DNAM-1 and NKG2D. *Front Immunol*. 2020 Jan 28;11:40. doi: 10.3389/fimmu.2020.00040.
3. Parlar A, Sayitoglu EC, Ozkazanc D, Georgoudaki AM, Pamukcu C, Aras M, Josey BJ, Chrobok M, Brannecki S, Zahedimaram P, Ikromzoda L, Alici E, Erman B, Duru AD, **Sutlu T**. Engineering antigen-specific NK cell lines against the melanoma-associated antigen tyrosinase via TCR gene transfer. *Eur J Immunol*. 2019 Aug;49(8):1278-1290. doi: 10.1002/eji.201948140. Epub 2019 May 17.
4. Chrobok M, Dahlberg CIM, Sayitoglu EC, Beljanski V, Nahi H, Gilljam M, Stellan B, **Sutlu T**, Duru AD, Alici E. Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells. *Cancers (Basel)*. 2019 Jan 10;11(1):69. doi: 10.3390/cancers11010069.

5. **Sutlu T**, Gilljam M, Stellan B and Alici E. Inhibition of intracellular anti-viral defense mechanisms augments lentiviral transduction of human natural killer cells: implications for gene therapy. *Human Gene Therapy*. 2012 Oct;23(10):1090-100.